IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs.

Abstract

Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial. The addition of this drug makes a ménage à trois of available drugs--comprising infliximab, adalimumab and golimumab--for the treatment of ulcerative colitis.

• Authors: Silvio Danese
• Journal: Nature reviews. Gastroenterology & hepatology (Nat Rev Gastroenterol Hepatol) Vol. 10 Issue 9 Pg. 511-2 (Sep 2013) ISSN: 1759-5053 [Electronic] England
• PMID: 23897288 (Publication Type: News)

Chemical References

• Antibodies, Monoclonal
• Tumor Necrosis Factor-alpha
• golimumab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Colitis, Ulcerative (drug therapy)
• Humans
• Randomized Controlled Trials as Topic
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)